Skip to main content

Recently, Menzo Havenga (CEO at Batavia Biosciences) was interviewed by the online magazine named “Startup Info”. This magazine is devoted to informing its readers on the booming startup ecosystem worldwide. The magazine desires to provide entrepreneurs who are looking for inspiration with relevant information, tips, and tricks. In the interview, Menzo elaborates on the impact of the COVID-19 pandemic on our company. At Batavia Biosciences, we are already preparing for the next virus outbreak.

Menzo Havenga: “We have been very fortunate that the COVID-19 pandemic thus far has had very limited effects on our staff and their families. As such, our operations have only been impacted minimally, and we have been able to meet our company deadlines and deliverables. If anything, the COVID-19 pandemic required us to work harder because the need for medical COVID-19 countermeasures is high. At the same time, we still deliver on all our other commitments.”

The global pressure on vaccine developers and manufacturers is very high

We require medical countermeasures for the current outbreak as fast as possible. At the same time, we need to prepare for the next epidemic. Because the question is not ‘if’ but ‘when’ the next virus outbreak will occur.

Menzo Havenga: “Owing to the expanding world population, intense global travel, and increased proximity to animals, the world is seeing a rapid increase in global virus outbreaks impacting human health. We have already been exposed to many outbreaks this millennium, such as SARS, MERS, Ebola, Mexican Flu, and COVID-19. Both the Ebola outbreak in Congo 2014 and the COVID-19 pandemic taught us that we require platform technologies to rapidly respond to outbreaks. Batavia is therefore heavily involved in the preparation of countermeasures. We develop safe and effective platform technologies that can be rapidly rolled-out.”

Read the full interview with Startup Info here.